 |
||
 |
 |
 |
| PGNX - (NASDAQ)
$10.03 - 0.16 |
Feb 3, 2012
4:00 PM ET |
Latest News
Nov 9, 2011
Progenics Pharmaceuticals Announces Third Quarter 2011 Financial Results
Nov 8, 2011
Progenics Pharmaceuticals to Participate in Investor Conferences
For the complete U.S. package insert for RELISTOR, please visit www.relistor.com 
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.
Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR by patients with chronic, non-cancer pain. A phase 3 clinical trial of an oral formulation of methylnaltrexone completed enrollment in mid-2011.